Healthy volunteers (prevention of RSV-associated lower respiratory tract illnesses (LRTIs)) MedDRA version: 21.1 Level: PT Classification code 10035732 Term: Pneumonia respiratory syncytial viral System Organ Class: 10021881 - Infections and infestations MedDRA version: 21.1 Level: PT Classification code 10038718 Term: Respiratory syncytial virus bronchiolitis System Organ Class: 10021881 - Infections and infestations MedDRA version: 21.1 Level: LLT Classification code 10066741 Term: Respirat
Conditions
Interventions
Product Name: RSVPreF3
Product Code: GSK3888550A
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: NA
Other descriptive name: GSKVx000000017076
Concentration unit
Sponsors
GlaxoSmithKline, S.A.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy Non-pregnant Adult Women from 18-49 YOA •Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol. •Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure. •A healthy female participant, as established by medical history and clinical examination, between and including 18 to 49 YOA at the time of the first study intervention administration. •Body mass index (based on participant’s report) 17.0 to 39.9 kg/m^2, inclusive for adult participants. •Female participants of childbearing potential may be enrolled in the study, if the participant: - has practiced adequate contraception for 1 month prior to study intervention administration, and - has a negative pregnancy test on the day of study intervention administration, and - has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administrations. •Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. Healthy non-pregnant Girls from 9-17 YOA •Participants and participants’ parent(s)/Legally Acceptable Representative(s) (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol. •Written or witnessed/thumb printed informed consent obtained from the participant*/parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure. -*Written informed consent obtained from parents/LARs and written informed assent obtained from the participant if she is less than legal age. The legal age is determined according to local regulations in each participating country. -In case the legal age is achieved during the conduct of the study, an additional written informed consent from the participant should be obtained at the time of the legal age. •A healthy female participant between and including 9 and 17 YOA at the time of the first study intervention administration. -Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy. •Body mass index by age between 5 percentile and 95 percentile (inclusive) for pediatric participants. •Female participants of childbearing potential may be enrolled in the study, if the participant: -has a negative pregnancy test on the day of study intervention administration, and is abstinent during the entire treatment period and for 1 month before and after completion of the study intervention administration series (and if so, this is to be documented in the source documents at each vaccination visit) -or has practiced adequate contraception for 1 month prior to study intervention administration and has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series. Are the trial subjects under 18? yes Number of subjects for this age range: 126 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 126 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Medical conditions •Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s). •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). •Current autoimmune disorder (based on medical history and physical examination;), for which the participant has received immune-modifying therapy within 6 months, before study vaccination. •Hypersensitivity to latex. •Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions, as determined by physical examination or medical history that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. •Significant or uncontrolled psychiatric illness. •Documented human immunodeficiency virus (HIV)-positive participant. •Any clinically significant* hematological parameter and/or biochemical laboratory abnormality from the test requested by the investigator based on medical judgment prior to enrolment -*The investigator should use his/her clinical judgment to decide whether the test is needed, and which abnormalities are clinically significant. If he/she decides to run this test, the investigator will need to review the test results before proceeding with the administration of the study vaccine. •Lymphoproliferative disorder or malignancy within 5 years before study vaccination (excluding effectively treated non-melanoma skin cancer). Prior/Concomitant therapy •Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before the first doses (Day -29 to Day 1), or their planned use during the study period. •Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention(s)* administration with the exception of any licensed influenza vaccine which may be administered = 15 days before or after study vaccinations (dTpa and RSV maternal vaccines). -*In case emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine (if it is used according to the local governmental recommendations and that the Sponsor is notified accordingly). Therefore, COVID-19 vaccines will be allowed, when administered = 15 days before or after study vaccinations (dTpa and RSV maternal vaccines). •Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab). •Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period. •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) to 2 months after first vaccination. For corticosteroid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: -To demonstrate non-inferiority of humoral immunogenicity following the administration of RSV maternal vaccine in terms of RSV A neutralizing antibody (Ab) titres between the pediatric (9-17 YOA) and adult (18-49 YOA) study groups -To evaluate the reactogenicity and safety following administration of RSV maternal vaccine and dTpa control vaccine in the pediatric and adult study groups up to 30 days (including day of study intervention administration);Secondary Objective: -To evaluate the immunogenicity (RSV MAT immunoglobulin G RSVPreF3 (IgG), RSV A Neutralizing Ab and RSV B Neutralizing Ab) of RSV maternal vaccine in the pediatric (9-17 YOA) study groups and 18-49 YOA (adult) groups -To evaluate the safety following administration of RSV maternal vaccine in the pediatric (9-17 YOA) and adult (18-49 YOA) study groups during the entire study period. (180 days post RSV maternal vaccination);Primary end point(s): A. RSV A neutralizing antibody titers at pre-dosing B. RSV A neutralizing antibody titers and between-group ratios at 30 days post-RSV MAT vaccine administration C. Percentage of participants reporting each solicited administration site event D. Percentage of participants reporting each solicited systemic event E. Percentage of participants reporting each unsolicited adverse event (AE) F. Percentage of participants reporting serious adverse events (SAEs) and medically attended adverse events (MAEs) G. Percentage of participants reporting AEs/SAEs/MAEs leading to study withdrawal;Timepoint(s) of evaluation of this end point: A. At pre-dosing (Day 1 or Day 31, depending on the vaccination schedule) B. At 30 days post-RSV MAT vaccine administration (Day 31 or Day 61, depending on the vaccination schedule) C., D. During the 7 days follow-up period post-each study intervention administration (study interventions administered at Day 1 and Day 31) E., F., G. During the 30 days follow-up period post-each study intervention administration (study int | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): A. RSV A neutralizing antibody titers and between-group ratios at 180 days post-RSV MAT vaccine administration B. RSV B neutralizing antibody titers (at pre-dosing, 30 days and 180 days post-RSV MAT vaccine administration) and between-group ratios (30 days and 180 days post-RSV MAT vaccine administration) C. RSV MAT IgG antibody concentrations (at pre-dosing, 30 days and 180 days post-RSV MAT vaccine administration) and between-group ratios (at 30 days and 180 days post-RSV MAT vaccine administration) D. Percentage of participants reporting SAEs from Day 1 until end of study E. Percentage of participants reporting AEs/SAEs leading to study withdrawal from Day 1 until end of study;Timepoint(s) of evaluation of this end point: A. At 180 days post-RSV MAT vaccine administration (Day 181 or Day 211, depending on the vaccination schedule) B., C. At pre-dosing (Day 1 or Day 31), 30 days post-RSV MAT vaccine administration (Day 31 or Day 61) and 180 days post-RSV MAT vaccine administration (Day 181 or Day 211) D., E. From Day 1 until end of study (Day 181 or Day 211, depending on the vaccination schedule) | — |
Countries
Finland, Germany, Panama, South Africa, Spain, United States
Contacts
Public ContactCentro de Información
GlaxoSmithKline
Outcome results
None listed